JP2022130637A5 - - Google Patents

Download PDF

Info

Publication number
JP2022130637A5
JP2022130637A5 JP2022105784A JP2022105784A JP2022130637A5 JP 2022130637 A5 JP2022130637 A5 JP 2022130637A5 JP 2022105784 A JP2022105784 A JP 2022105784A JP 2022105784 A JP2022105784 A JP 2022105784A JP 2022130637 A5 JP2022130637 A5 JP 2022130637A5
Authority
JP
Japan
Prior art keywords
antigen
immunogenic
nomv
immunogenic conjugate
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022105784A
Other languages
English (en)
Japanese (ja)
Other versions
JP7439174B2 (ja
JP2022130637A (ja
Filing date
Publication date
Priority claimed from GBGB1619946.5A external-priority patent/GB201619946D0/en
Priority claimed from GBGB1712096.5A external-priority patent/GB201712096D0/en
Priority claimed from PCT/EP2017/080145 external-priority patent/WO2018096007A2/en
Application filed filed Critical
Publication of JP2022130637A publication Critical patent/JP2022130637A/ja
Publication of JP2022130637A5 publication Critical patent/JP2022130637A5/ja
Application granted granted Critical
Publication of JP7439174B2 publication Critical patent/JP7439174B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022105784A 2016-11-25 2022-06-30 免疫原性コンジュゲート及びその使用 Active JP7439174B2 (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB1619946.5 2016-11-25
GBGB1619946.5A GB201619946D0 (en) 2016-11-25 2016-11-25 Conjugated immunogenic derivatives and use thereof
GB1712096.5 2017-07-27
GBGB1712096.5A GB201712096D0 (en) 2017-07-27 2017-07-27 Immunogenic conjugates and use thereof
PCT/EP2017/080145 WO2018096007A2 (en) 2016-11-25 2017-11-23 Immunogenic conjugates and use thereof
JP2019527901A JP7100031B2 (ja) 2016-11-25 2017-11-23 免疫原性コンジュゲート及びその使用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019527901A Division JP7100031B2 (ja) 2016-11-25 2017-11-23 免疫原性コンジュゲート及びその使用

Publications (3)

Publication Number Publication Date
JP2022130637A JP2022130637A (ja) 2022-09-06
JP2022130637A5 true JP2022130637A5 (cg-RX-API-DMAC7.html) 2022-09-30
JP7439174B2 JP7439174B2 (ja) 2024-02-27

Family

ID=60702606

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019527901A Active JP7100031B2 (ja) 2016-11-25 2017-11-23 免疫原性コンジュゲート及びその使用
JP2022105784A Active JP7439174B2 (ja) 2016-11-25 2022-06-30 免疫原性コンジュゲート及びその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019527901A Active JP7100031B2 (ja) 2016-11-25 2017-11-23 免疫原性コンジュゲート及びその使用

Country Status (9)

Country Link
US (1) US12036285B2 (cg-RX-API-DMAC7.html)
EP (1) EP3544625A2 (cg-RX-API-DMAC7.html)
JP (2) JP7100031B2 (cg-RX-API-DMAC7.html)
CN (1) CN110214022A (cg-RX-API-DMAC7.html)
BE (1) BE1025210B1 (cg-RX-API-DMAC7.html)
BR (1) BR112019010227A2 (cg-RX-API-DMAC7.html)
CA (1) CA3044569A1 (cg-RX-API-DMAC7.html)
MX (1) MX2019006104A (cg-RX-API-DMAC7.html)
WO (1) WO2018096007A2 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE052751T2 (hu) * 2016-11-25 2021-05-28 Glaxosmithkline Biologicals Sa Natív OMV-antigén konjugátumok és alkalmazásuk
US12036285B2 (en) 2016-11-25 2024-07-16 Glaxosmithkline Biologicals Sa Immunogenic conjugates and use thereof
GB201712824D0 (en) * 2017-08-10 2017-09-27 Glaxosmithkline Biologicals Sa Multi-functionalized nOMV Conjugates
CN111358942A (zh) * 2018-12-25 2020-07-03 国家纳米科学中心 一种疫苗及其制备方法
JP7462864B2 (ja) * 2019-04-19 2024-04-08 国立感染症研究所長 メンブレンヴェシクル
WO2021031270A1 (zh) * 2019-08-22 2021-02-25 四川大学 细菌膜囊泡及其分离制备系统和方法
US12649150B2 (en) 2024-05-29 2026-06-09 Cassiopea LLC Enzyme-decorated nanocatalysts

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4271147A (en) 1980-01-10 1981-06-02 Behringwerke Aktiengesellschaft Process for the isolation of membrane proteins from Neisseria meningitidis and vaccines containing same
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
NZ214503A (en) 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
US4707543A (en) 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
EP0467714A1 (en) 1990-07-19 1992-01-22 Merck & Co. Inc. The class II protein of the outer membrane of neisseria meningitidis
CA2264970A1 (en) 1998-03-10 1999-09-10 American Cyanamid Company Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria
NZ571167A (en) 1999-04-30 2010-05-28 Novartis Vaccines & Diagnostic Fragments from Neisseria protein ORF 953 and their use in medicaments and diagnostic reagents
AU2818101A (en) 2000-01-25 2001-08-07 University Of Queensland, The proteins comprising conserved regions of neisseria meningitidis surface antigen NhhA
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
WO2006124712A2 (en) 2005-05-16 2006-11-23 Merck & Co., Inc. A method for improving the immunogenicity of plasmodium antigens
WO2006123164A2 (en) 2005-05-19 2006-11-23 The Edward Jenner Institute For Vaccine Research Lps-binding and bactericidal cytokines and interferons
EP2729167B1 (en) * 2011-07-07 2018-03-14 De Staat der Nederlanden, vert. door de Minister van VWS A process for detergent-free production of outer membrane vesicles of a gram-negative bacterium
EP2852414B9 (en) 2012-05-22 2020-12-09 GlaxoSmithKline Biologicals SA Meningococcus serogroup x conjugate
EP2870974A1 (en) * 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
EP3223847A1 (en) * 2014-11-28 2017-10-04 Janssen Vaccines & Prevention B.V. Meningitis b vaccine
US11066453B2 (en) * 2015-05-18 2021-07-20 Biomvis Srl Immunogenic compositions containing bacterial outer membrane vesicles and therapeutic uses thereof
EP3482387B1 (en) 2016-07-11 2025-09-03 BOE Technology Group Co., Ltd. Chip on film, flexible display apparatus having the same, and fabricating method thereof
US12036285B2 (en) 2016-11-25 2024-07-16 Glaxosmithkline Biologicals Sa Immunogenic conjugates and use thereof
HUE052751T2 (hu) 2016-11-25 2021-05-28 Glaxosmithkline Biologicals Sa Natív OMV-antigén konjugátumok és alkalmazásuk

Similar Documents

Publication Publication Date Title
JP7796163B2 (ja) 肺炎連鎖球菌多糖-タンパク質コンジュゲートの免疫原性の増強
JP7268125B2 (ja) コンジュゲート化莢膜糖類抗原を含む免疫原性組成物、それを含むキットおよびこれらの使用
US20240131136A1 (en) Vaccine
Trotter et al. Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae
TWI281403B (en) Vaccine
TWI789357B (zh) 多價肺炎球菌多醣-蛋白質共軛物組成物(二)
CN102869375B (zh) 包含与载体蛋白缀合的肺炎链球菌多糖的免疫原性组合物
EA014165B1 (ru) Пневмококковая полисахаридная конъюгатная вакцина
TWI770044B (zh) 多價肺炎球菌多醣-蛋白質共軛物組成物(一)
BR112020014978A2 (pt) Composição de conjugado polissacarídeo-proteína pneumocócico multivalente
JP2022130637A (ja) 免疫原性コンジュゲート及びその使用
RU2774891C2 (ru) Повышение иммуногенности конъюгатов полисахарид streptococcus pneumoniae-белок
CN122005771A (zh) 31价肺炎球菌荚膜多糖的组合物及其应用
CN116898960A (zh) 细菌多糖蛋白缀合物及其应用
BR122026004203A2 (pt) Método para preparar um conjugado imunogênico de streptococcus pneumoniae serotipo 9n